Hitomi Sezaki

Summary

Affiliation: Toranomon Hospital
Country: Japan

Publications

  1. ncbi request reprint Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:1276-83. 2006
  2. doi request reprint Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
  3. doi request reprint An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
  4. ncbi request reprint Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 49:339-45. 2006
  5. ncbi request reprint Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
  6. ncbi request reprint Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
  7. ncbi request reprint Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
  8. ncbi request reprint Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
  9. ncbi request reprint Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
  10. doi request reprint Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008

Collaborators

Detail Information

Publications99

  1. ncbi request reprint Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:1276-83. 2006
    ..36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long-term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B...
  2. doi request reprint Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  3. doi request reprint An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
    ..Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved...
  4. ncbi request reprint Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 49:339-45. 2006
    ..To evaluate the long-term effects of corticosteroid withdrawal therapy (CSWT) in young adult Japanese patients with chronic hepatitis B (CH-B) virus infection...
  5. ncbi request reprint Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  6. ncbi request reprint Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  7. ncbi request reprint Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
    ..The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load...
  8. ncbi request reprint Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  9. ncbi request reprint Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  10. doi request reprint Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
    ..The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) antibody-positive elderly patients with chronic hepatitis without cirrhosis...
  11. ncbi request reprint Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..73; 95% CI 1.77-4.20; P < 0.001), the patient had pre-diabetes (hazard ratio 2.19; 95% CI 1.43-3.37; P < 0.001), and age was >or=50 years (hazard ratio 2.10; 95% CI 1.38-3.18; P < 0.001)...
  12. ncbi request reprint Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  13. doi request reprint A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  14. ncbi request reprint A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
    ....
  15. ncbi request reprint Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  16. ncbi request reprint Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
    ..The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients...
  17. doi request reprint Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  18. doi request reprint HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    Tetsuya Hosaka
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 30:1461-70. 2010
    ....
  19. doi request reprint Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:41-8. 2010
    ....
  20. doi request reprint Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
    ....
  21. ncbi request reprint Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  22. doi request reprint Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  23. ncbi request reprint Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:83-90. 2006
    ....
  24. ncbi request reprint Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1155-60. 2007
    ..The aim of this study was to evaluate whether or not combination therapy of pegylated interferon (IFN) and ribavirin for chronic hepatitis (CH) C patients enhances the serum level of KL-6, a sensitive marker for interstitial pneumonia...
  25. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  26. ncbi request reprint Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  27. ncbi request reprint Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  28. ncbi request reprint Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:368-74. 2007
    ..The aim of this study was to investigate the factors associated with the response of lamivudine-resistant hepatitis B virus (HBV) during combination therapy with adefovir dipivoxil plus lamivudine...
  29. doi request reprint Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  30. doi request reprint Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  31. ncbi request reprint Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:341-52. 2006
    ..More substitutions in the rt region and the other proteins may be related to the emergence of severe hepatitis caused by lamivudine-resistant virus...
  32. doi request reprint Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  33. doi request reprint Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  34. doi request reprint Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy
    Yuya Seko
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 56:13-21. 2013
    ....
  35. doi request reprint Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 83:1016-22. 2011
    ..This study emphasizes the importance of detection of aa substitutions in the core region before antiviral therapy...
  36. doi request reprint Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  37. doi request reprint Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan akuta gi umin ac jp
    Intervirology 53:188-92. 2010
    ..In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2...
  38. doi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  39. ncbi request reprint The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:355-60. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for chronic hepatitis C patients with low virus load...
  40. ncbi request reprint Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1301-7. 2008
    ..The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection...
  41. ncbi request reprint Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1637-43. 2008
    ..The aim of the present study was to determine the rate of hepatocarcinogenesis and the risk factor in sustained virological responders...
  42. ncbi request reprint Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
    Takashi Someya
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 41:1206-13. 2006
    ..Hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) often recurs after surgical or medical treatment...
  43. ncbi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs...
  44. ncbi request reprint Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:174-82. 2005
    ..Comparison of virological and biochemical relapse in patients with chronic hepatitis B, based on continuation or discontinuation of lamivudine monotherapy...
  45. ncbi request reprint Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:491-8. 2005
    ..None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used...
  46. doi request reprint Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 56:2134-41. 2012
    ..In patients of Arg70 at the initial visit, the cumulative change rates from Arg70 to Gln70(His70) in IL28B rs8099917 non-TT genotype were significantly higher than those in the TT genotype...
  47. doi request reprint Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 23:1739-46. 2008
    ..The aim of this retrospective study was to examine the relationship between diabetes mellitus and recurrence of hepatocellular carcinoma after potentially curative therapy for hepatocellular carcinoma with nonviral hepatitis...
  48. doi request reprint The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:265-9. 2008
    ..The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load...
  49. ncbi request reprint The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1085-90. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for type C cirrhotic patients with genotype 2a and low virus load...
  50. ncbi request reprint Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    Intervirology 49:82-90. 2006
    ..The anticarcinogenic capacity of interferon (IFN) was assessed in a cohort of Japanese patients with chronic hepatitis C en masse...
  51. ncbi request reprint Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 40:688-96. 2005
    ..The long-term effects of multi-course interferon (IFN) monotherapy in patients infected with hepatitis C virus (HCV) are still unclear...
  52. ncbi request reprint Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:459-65. 2006
    ....
  53. doi request reprint Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 53:415-21. 2011
    ..039), but the total RBV dose was no different between them (49 ± 17% and 54 ± 18% of the target, P = 0.531). Sustained virological response (SVR) was achieved in 70% and 64% of them, respectively (P = 0.724)...
  54. ncbi request reprint Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:977-85. 2006
    ..To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase, long-term observation was performed in a retrospective cohort...
  55. ncbi request reprint Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1827-32. 2007
    ..The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C...
  56. ncbi request reprint Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  57. ncbi request reprint Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
    Kiminori Uka
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Gastroenterol 41:470-5. 2006
    ..The aim of this study was to analyze the response to interferon (IFN) monotherapy in young HCV patients...
  58. doi request reprint Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 85:1028-36. 2013
    ..It is concluded that it is difficult to predict at baseline the emergence of telaprevir-resistant variants after commencement of triple therapy in prior non-responders of HCV genotype 1, even with the use of ultra-deep sequencing...
  59. doi request reprint Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    Hepatology 57:964-73. 2013
    ..T2DM caused a 1.70-fold enhancement in the development of malignancies other than HCC...
  60. doi request reprint Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 56:37-45. 2013
    ..Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear...
  61. doi request reprint Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:231-41. 2012
    ..To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b)...
  62. doi request reprint Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Gastroenterol 107:253-61. 2012
    ....
  63. doi request reprint Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:390-5. 2010
    ..J. Med. Virol. 82:390-395, 2010. (c) 2010 Wiley-Liss, Inc...
  64. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
    ....
  65. ncbi request reprint Hepatitis B virus-related hepatocellular carcinogenesis and its prevention
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 48:29-38. 2005
    ..026). A significant decrease or loss of serum HBV-DNA stops HCC development, and its sequential analysis could be very useful both in the prediction and early detection of small HCC...
  66. ncbi request reprint Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection
    Yusuke Kawamura
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 40:901-6. 2005
    ....
  67. ncbi request reprint Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    Dig Dis Sci 55:2070-6. 2010
    ..Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known...
  68. doi request reprint Clinical and virological effects of long-term (over 5 years) lamivudine therapy
    Yoshimasa Hashimoto
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 82:684-91. 2010
    ..Moreover, after the emergence of YMDD mutants, short latency to the emergence of YMDD mutant, mixed type mutants, and low baseline ALT level were associated with elevation of ALT or viral load...
  69. ncbi request reprint Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:550-8. 2005
    ..Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis...
  70. ncbi request reprint Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1472-7. 2007
    ..These results indicate that loss of HBsAg occurs in a minority (3.5%) of patients with chronic hepatitis B who receive lamivudine therapy and more frequently in those with lower HBsAg titers and older ages at the start of treatment...
  71. doi request reprint Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 31:692-9. 2011
    ..Stage progression of 374 small hepatocellular carcinomas (HCC) was retrospectively analysed...
  72. ncbi request reprint Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
    ....
  73. ncbi request reprint Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..In Japan, there are few studies of long-term (more than 1 month) interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy and predictors of response to 6-month IFN therapy...
  74. ncbi request reprint Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load
    Yoshio Katamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1827-34. 2008
    ....
  75. ncbi request reprint Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:19-25. 2004
    ..We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not...
  76. ncbi request reprint Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:362-9. 2004
    ....
  77. ncbi request reprint Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    Intervirology 48:138-44. 2005
    ..The purpose of this clinical retrospective cohort study was to determine the most suitable ribavirin concentration on combination therapy of interferon (IFN)-ribavirin...
  78. ncbi request reprint Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:71.e9-16. 2006
    ..The aim of this study was to elucidate the long-term outcome after hepatitis B surface antigen (HBsAg) seroclearance in a large number of Japanese patients...
  79. ncbi request reprint Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Cancer 106:636-47. 2006
    ..Advances in imaging technology have enhanced the detection of small nodular lesions during the course of chronic liver disease...
  80. ncbi request reprint Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1095-102. 2007
    ..9 compared with mild or moderate fibrosis. In conclusion, long-term IFN therapy for aged patients with chronic HCV infection is effective in decreasing the serum AFP level and preventing hepatocarcinogenesis...
  81. ncbi request reprint Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection
    Tomokazu Kawaoka
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:395-401. 2007
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in elderly patients with chronic HBV infection...
  82. ncbi request reprint Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
    Kenji Ikeda
    Department of Gastroenterology, Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 44:1089-97. 2006
    ..To estimate hepatocarcinogenesis rates in patients with hepatitis C virus (HCV)-related cirrhosis, an accurate prediction table was created...
  83. ncbi request reprint Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo, Japan
    J Clin Virol 39:149-52. 2007
  84. ncbi request reprint Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:161-5. 2007
    ..The aim of this study was to elucidate the presence of serum hepatitis B virus (HBV) DNA at a prolonged time after seroclearance of hepatitis B surface antigen (HBsAg)...
  85. ncbi request reprint Prolonged hepatitis after acute infection with genotype H hepatitis B virus
    Norio Chihara
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1847-51. 2007
    ..Genotype H, the newest type of hepatitis B, could be the type which shows a poor response to lamivudine. The present paper is the first report, describing the clinical course of acute hepatitis B with genotype H from onset to remission...
  86. ncbi request reprint Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:550-6. 2004
    ....
  87. ncbi request reprint Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 73:7-12. 2004
    ..The present study provides important information for the development of more effective and rational long-term lamivudine therapy for HBeAg-positive chronic hepatitis B patients infected exclusively with genotype..
  88. ncbi request reprint Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis
    Hiromi Ooga
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:1078-84. 2004
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in Japanese patients with cirrhosis, and to evaluate the clinical course after the emergence of YMDD mutants...
  89. ncbi request reprint Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up
    Nobuhiko Hiraga
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 75:240-8. 2005
    ..Genotype 2 is an important factor for ALT flare-up. However, we could not directly relate ALT flare-up to these alterations in amino acids of the core region, HVR1, and ISDR...
  90. ncbi request reprint Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:1090-4. 2004
    ..In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy...
  91. ncbi request reprint Usefulness of the serum KL-6 assay in patients with hepatitis C virus
    Yasuji Arase
    Department of Gastroenterology and Hepatic Research Unit, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:400-4. 2005
    ..The aim of this study is to evaluate the serum level of KL-6 in hepatitis C virus (HCV)-positive patients with chronic liver disease...
  92. ncbi request reprint Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, the Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Liver Int 27:353-9. 2007
    ..To evaluate the efficacy of temporary balloon arterial occlusion during radiofrequency ablation (RFA), randomized controlled trial was performed...
  93. ncbi request reprint Efficacy of interferon therapy in elderly patients with chronic hepatitis C
    Rikako Koyama
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Tokyo, Japan
    Intervirology 49:121-6. 2006
    ..We assessed the efficacy and safety of interferon (IFN) monotherapy in 84 elderly patients aged > or =65 years with chronic hepatitis C in a retrospective cohort study...
  94. ncbi request reprint New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 28:214-9. 2008
    ..The aim of this study was to investigate experimentally the efficacy of a modified extension procedure...
  95. doi request reprint Change of hepatitis B virus genotypes in acute and chronic infections in Japan
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1880-4. 2008
    ..Based on genotypes/subgenotypes changing with time, the resurgence of hepatitis B could be attributed to infections, with foreign HBV genotypes/subgenotypes, spreading swiftly by sexual contact...
  96. ncbi request reprint Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 120:1034-41. 2007
    ..The aim of this retrospective study was to determine the incidence of malignant lymphoma and the relationship between malignant lymphoma and viral elimination in patients with HCV...
  97. ncbi request reprint Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 21:183-90. 2006
    ..To elucidate the origin of the neovascular structure found in well-differentiated hepatocellular carcinoma (HCC), an immunohistochemical study was performed on sequential thin section specimens...
  98. doi request reprint Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 80:1302-7. 2008
    ..2% at the second year, and 57.6% at the fifth year. The present study suggests that a serum albumin level of >or=3.5 g/dl and cyclic etidronate treatment reduce the appearance of bone fracture...
  99. ncbi request reprint Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:493-500. 2003
    ..if IFN is expected to be efficacious on the basis of genotype of HCV-RNA level; even if there is acute exacerbation of type-C chronic hepatitis, IFN should be re-administered in the HCV-RNA level has dropped subsequently...